BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab cancer data

Researchers at the Dana-Farber Cancer Institute and colleagues reported data from a meta-analysis of 3,784 breast cancer patients in randomized trials of Avastin showing that the overall incidence for congestive heart failure (CHF) was 1.6% for those receiving Avastin vs. 0.4% for placebo (p=0.001). In subgroup analyses, there were no significant differences in CHF incidence or risk...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >